Case Studies

Challenge: A private equity fund approaching an investment in a Phase III asset required an expert evaluation of the likelihood of success in the Phase III trial. The molecule, targeted at two CNS...

Challenge: A private equity investor was considering a transaction in a company supplying therapeutic proteins derived from biological sources for the treatment of numerous diseases in the...

Challenge: A company developing a portfolio of therapeutic cannabinoids for neurological conditions was seeking a stock exchange listing and asked Alacrita to develop documentation supporting its...

Oncology Scientific Advisory Board An emerging drug discovery company, with a core expertise in molecular modelling, had developed a small molecule inhibitor of a novel cancer metabolism target. The...

A pharmaceutical company asked Alacrita to assist in providing an HTA/payer perspective on the proposed label and mechanism of action/clinical positioning for its pain drug, to ensure that the Phase...

A Cambridge MA based therapeutics company asked Alacrita to provide feedback on the Phase III protocol design for its lead drug, specifically from an EU payer perspective. Alacrita’s expert European...

A leading research institute developing novel approaches for production of ophthalmic treatments asked Alacrita to conduct a market and competitive assessment of the current supplier base and...

A university research team had worked for a number of years on the development of a novel interventional cardiology device. Recent progress had been made with pre-clinical testing on pigs, as well as...

Challenge: A clinical stage biotech needed support with its regulatory due diligence activities for products in the respiratory field.

Alacrita was asked to assess the market opportunity for a novel anaemia therapy in order to facilitate discussions with potential partners. Alacrita conducted the assessment in two stages.

A life science venture capital fund was contemplating investing in advanced plasma product opportunities being developed by a biopharmaceutical company. Alacrita was commissioned to provide a reality...

10111A world-leading manufacturer of wound care products was assessing opportunities in advanced wound care, and has mapped regulatory pathways that pertained to various classes of product. Having...